Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2

Endocrinology

Volumn 153, Issue 6, 2012, Pages 2747-2755

  Parry, Jesse J ^a   Chen, Ronald ^a   Andrews, Rebecca ^a   Lears, Kimberly A ^a   Rogers, Buck E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; ARGININE; ASPARTIC ACID; CALCIUM; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; LEUCINE; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR 2;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CALCIUM TRANSPORT; CONTROLLED STUDY; DISSOCIATION CONSTANT; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LIGAND BINDING; MUTANT; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; WILD TYPE;

ALANINE; AMINO ACID SUBSTITUTION; AMINO ACIDS; ARGININE; ASPARTIC ACID; BINDING SITES; BINDING, COMPETITIVE; CALCIUM; CELL LINE, TUMOR; CYCLIC AMP; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GTP-BINDING PROTEINS; HUMANS; KINETICS; LEUCINE; POINT MUTATION; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOMATOSTATIN;

EID: 84861312469     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1662     Document Type: Article

References (53)

1. Krulich L, Dhariwal AP, McCann SM 1968 Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783-790
2. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB 1995 The somatostatin receptor family. Life Sci 57: 1249-1265
3. Reisine T, Bell GI 1995 Molecular biology of somatostatin receptors. Endocr Rev 16:427-442
4. Patel YC 1997 Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 20:348-367 (Pubitemid 27410043)
5. Patel YC 1999 Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198 (Pubitemid 29362641)
6. Olias, G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W 2004 Regulation and function of somatostatin receptors. J Neurochem 89:1057-1091 (Pubitemid 38720193)
7. Lamberts SW, de Herder WW, Hofland LJ 2002 Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 13:451-457 (Pubitemid 36733940)
8. Hofland LJ, Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47 (Pubitemid 36223278)
9. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254 (Pubitemid 26030676)
10. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017 (Pubitemid 37540581)
11. Lamberts SW, Krenning EP, Reubi JC 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-482
12. Patch D, BurroughsA2002 Vapreotide in variceal bleeding. J Hepatol 37:167-168
13. GoldenbergDM2002 Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713 (Pubitemid 34507123)
14. Labeur M, Theodoropoulou M, Sievers C, Paez-Pereda M, Castillo V, Arzt E, Stalla GK 2006 New aspects in the diagnosis and treatment of Cushing disease. Front Horm Res 35:169-178 (Pubitemid 44024250)
15. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H 2001 Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28: 1751-1757
16. Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R 2001 New trends in peptide receptor radioligands. Q J Nucl Med 45:153-159 (Pubitemid 32640389)
17. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP 2006 Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 9:243-248 (Pubitemid 44742286)
18. Rogers BE, Parry JJ, Andrews R, Cordopatis P, Nock BA, Maina T 2005 MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and 94mTc-Demotate 1. J Nucl Med 46:1889-1897 (Pubitemid 46196652)
19. Parry JJ, Eiblmaier M, Andrews R, Meyer LA, Higashikubo R, Anderson CJ, Rogers BE 2007 Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells. Mol Imaging 6:56-67 (Pubitemid 46642491)
20. Chen R, Parry JJ, Akers WJ, Berezin MY, El Naqa IM, Achilefu S, Edwards WB, Rogers BE 2010 Multimodality imaging of gene transfer with a receptor-based reporter gene. J Nucl Med 51:1456-1463
21. Kumar U, GrantM2010 Somatostatin and somatostatin receptors. Results Probl Cell Differ 50:137-184
22. Meyerhof W 1998 The elucidation of somatostatin receptor functions: a current view. Rev Physiol Biochem Pharmacol 133:55-108
23. Florio T 2008 Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol 286:40-48 (Pubitemid 351680234)
24. Kong H, Raynor K, Yasuda K, Bell GI, Reisine T 1993 Mutation of an aspartate at residue 89 in somatostatin receptor subtype 2 prevents Na+ regulation of agonist binding but does not alter receptor-G protein association. Mol Pharmacol 44:380-384 (Pubitemid 23252244)
25. Strnad J, Hadcock JR 1995 Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Biochem Biophys Res Commun 216:913-921
26. Han L, Yang D, Kundra V 2007 Signaling can be uncoupled from imaging of the somatostatin receptor type 2. Mol Imaging 6:427-437
27. Schwartkop CP, Kreienkamp HJ, Richter D 1999 Agonist-independent internalization and activity of a c-terminally truncated somatostatin receptor subtype 2 (δ349). J Neurochem 72:1275-1282 (Pubitemid 29085044)
28. Vanetti M, Vogt G, Höllt V 1993 The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization. FEBS Lett 331:260-266 (Pubitemid 23287284)
29. Rogers BE, Chaudhuri TR, Reynolds PN, Della Manna D, Zinn KR 2003 Non-invasive γ camera imaging of gene transfer using an adenoviral vector encoding an epitope tagged receptor as a reporter. Gene Ther 10:105-114 (Pubitemid 36582582)
30. Kundra V, Mannting F, Jones AG, Kassis AI 2002 Noninvasive monitoring of somatostatin receptor subtype 2 chimeric gene transfer. J Nucl Med 43:406-412 (Pubitemid 34208104)
31. Rogers BE, McLean SF, Kirkman RL, Della Manna D, Bright SJ, Olsen CC, Myracle AD, Mayo MS, Curiel DT, Buchsbaum DJ 1999 In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clin Cancer Res 5:383-393 (Pubitemid 29085192)
32. Lopez F, Estève JP, Buscail L, Delesque N, Saint-Laurent N, Théveniau M, Nahmias C, Vaysse N, Susini C 1997 The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J Biol Chem 272:24448-24454 (Pubitemid 27418653)
33. Hortala M, Ferjoux G, Estival A, Bertrand C, Schulz S, Pradayrol L, Susini C, Clemente F 2003 Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform. J Biol Chem 278:20574-20581 (Pubitemid 36806355)
34. Grant M, Collier B, KumarU2004 Agonist-dependent dissociation of human somatostatin receptor 2 dimers. J Biol Chem 279:36179-36183 (Pubitemid 39128952)
35. Durán-Prado M, Bucharles C, Gonzalez BJ, Vázquez- Martínez R, Martínez-Fuentes AJ, García-Navarro S, Rhodes SJ, Vaudry H, Malagón MM, Castaño JP 2007 Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology 148:411-421 (Pubitemid 46021473)
36. Pfeiffer M, Koch T, Schröder H, Klutzny M, Kirscht S, Kreienkamp HJ, Höllt V, Schulz S 2001 Homo- and heterodimerization of somatostatin receptor subtypes. J Biol Chem 276:14027-14036
37. Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U 2008 cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol 22:2278-2292
38. Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC 1992 Sequence alignment of the G-protein coupled receptor superfamily. DNA Cell Biol 11:1-20
39. Liang Q, Satyamurthy N, Barrio JR, Toyokuni T, Phelps MP, Gambhir SS, Herschman HR 2001 Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther 8:1490-1498 (Pubitemid 32994660)
40. Huttenrauch F, Nitzki A, Lin FT, Höning S, Oppermann M 2002 β-Arrestin binding to CC chemokine receptor 5 requires multiple c-terminal receptor phosphorylation sites and involves a conserved asp-arg-tyr sequence motif. J Biol Chem 277:30769-30777 (Pubitemid 34970774)
41. Dixon RA, Sigal IS, Strader CD 1988 Structure-function analysis of the β-adrenergic receptor. Cold Spring Harb Symp Quant Biol 53: 487-497
42. Fraser CM, Chung FZ, Wang CD, Venter JC 1988 Site-directed mutagenesis of human β-adrenergic receptors: substitution of aspartic acid-130 by asparagine produces a receptor with high-affinity agonist binding that is uncoupled from adenylate cyclase. Proc Natl Acad Sci USA 85:5478-5482
43. Moore SA, Patel AS, Huang N, Lavin BC, Grammatopoulos TN, Andres RD, Weyhenmeyer JA 2002 Effects of mutations in the highly conserved DRY motif on binding affinity, expression, and G-protein recruitment of the human angiotensin II type-2 receptor. Mol Brain Res 109:161-167 (Pubitemid 36078381)
44. Clayton CC, Bruchas MR, Lee ML, Chavkin C 2010 Phosphorylation of theμ-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy. Mol Pharmacol 77:339-347
45. Wang CD, Buck MA, FraserCM1991 Site-directed mutagenesis of α 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol 40:168-179
46. Elling CE, Nielsen SM, Schwartz TW 1995 Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor. Nature 374:74-77
47. Fraser CM, Wang CD, Robinson DA, Gocayne JD, Venter JC 1989 Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol Pharmacol 36:840-847 (Pubitemid 20019555)
48. Arora KK, Sakai A, Catt KJ 1995 Effects of second intracellular loop mutations on signal transduction and internalization of the gonadotropin- releasing hormone receptor. J Biol Chem 270:22820-22826
49. Shi W, Sports CD, Raman D, Shirakawa S, Osawa S, Weiss ER 1998 Rhodopsin arginine-135 mutants are phosphorylated by rhodopsin kinase and bind arrestin in the absence of 11-cis-retinal. Biochemistry 37:4869-4874 (Pubitemid 28175968)
50. Ben-Shlomo A, Pichurin O, Barshop NJ, Wawrowsky KA, Taylor J, Culler MD, Chesnokova V, Liu NA, Melmed S 2007 Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol 21:2565-2578 (Pubitemid 47529366)
51. Fahmy K, Sakmar TP, Siebert F 2000 Transducin-dependent protonation of glutamic acid 134 in rhodopsin. Biochemistry 39: 10607-10612 (Pubitemid 30655939)
52. Takano K, Yasufuku-Takano J, Teramoto A, Fujita T 1997 Gi3 mediates somatostatin-induced activation of an inwardly rectifying K+ current in human growth hormone-secreting adenoma cells. Endocrinology 138:2405-2409 (Pubitemid 27215243)
53. Ikeda SR, SchofieldGG1989 Somatostatin blocks a calcium current in rat sympathetic ganglion neurons. J Physiol 409:221-240 (Pubitemid 19052981)